Altium Capital Management LP Immunic, Inc. Transaction History

Altium Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.13 - $12.25 $939,000 - $3.68 Million	-300,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$9.54 - $14.26 $162,180 - $242,420	-17,000 Reduced 5.36%	300,000 $3.39 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $2.09 Million - $2.92 Million	284,979 Added 889.98%	317,000 $3.03 Million
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $257,769 - $425,559	32,021 New	32,021 $320,000
Q1 2021 May 06, 2021	SELL	$14.21 - $25.3 $3.47 Million - $6.18 Million	-244,155 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$14.8 - $20.37 $3.61 Million - $4.97 Million	244,155 New	244,155 $3.73 Million

56M

4.7K

311K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $36.1M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.